ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

INKT MiNK Therapeutics Inc

0,9499
0,0092 (0,98%)
07 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
MiNK Therapeutics Inc INKT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,0092 0,98% 0,9499 23:43:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,9405 0,9235 0,9774 0,9301 0,9407
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202413:30GLOBEMiNK to Provide Corporate Update and First Quarter 2024..
08.4.202418:00GLOBEMiNK Therapeutics Announces Promising Preclinical Activity..
21.3.202412:26IHMARKETNEWSU.S. Index Futures Rise as Fed’s Dovish Outlook Spurs..
21.3.202412:00GLOBEMiNK Reports Fourth Quarter and Year-End 2023 Results
07.3.202413:30GLOBEMiNK to Provide Corporate Update and Fourth Quarter & Full..
06.3.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:05EDGAR2Form 8-K - Current report
14.2.202414:00EDGAR2Form 8-K - Current report
14.2.202414:00GLOBEFirst Refractory Gastric Cancer Patient Dosed in Phase 2..
06.2.202414:00GLOBEMiNK Therapeutics' AgenT-797 Shows Promising Results in the..
30.1.202414:00GLOBEMiNK’s AgenT-797 Offers New Hope in Overcoming ICI..
19.1.202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202313:30GLOBEImmunoScape and MiNK Therapeutics Collaborate to Accelerate..
06.12.202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.11.202313:00EDGAR2Form 8-K - Current report
09.11.202313:00GLOBEMiNK Therapeutics Reports Third Quarter 2023 Results
03.11.202317:00GLOBEMiNK Therapeutics Presents Clinical Activity and Long-Term..
30.10.202313:00GLOBEMiNK to Provide Third Quarter 2023 Financial Report and..
17.10.202322:15EDGAR2Form 8-K - Current report
27.9.202315:05GLOBEMiNK Therapeutics To Present Data Update From Allogeneic..
06.9.202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.9.202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.8.202314:30GLOBEMiNK Therapeutics to Participate in September Investor..
11.8.202313:44EDGAR2Form S-8 - Securities to be offered to employees in employee..
10.8.202313:30EDGAR2Form 8-K - Current report
10.8.202313:30GLOBEMiNK Therapeutics Reports Second Quarter 2023 Results
10.8.202313:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28.7.202314:30GLOBEMiNK to Provide Second Quarter 2023 Financial Report and..
05.6.202313:30GLOBEMiNK Therapeutics Announces Virtual Annual Shareholders..
22.5.202314:30GLOBEMiNK Presents Clinical Data on Allogeneic iNKT Cells..
18.5.202314:30GLOBEMiNK's Novel FAP-CAR-iNKT Presented at ASGCT
11.5.202314:00GLOBEMiNK Therapeutics Reports Corporate Update and First Quarter..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock